SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 651.80-0.3%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotechwantabe who wrote (3500)4/27/2023 6:54:34 PM
From: A.J. Mullen   of 3557
 
Q1 Roche Zabysmo doing well +432. Does it impact Eylea growth? Probably what’s scaring the market.

What's your thinking (or anyone else's) with respect to Unity's threat to Eylea? ir.unitybiotechnology.com. They're planning a head to head trial against Eylea in diabetic macular edema. It's a smaller market than wet AMD. Unity failed in a trial against Eylea in wet AMD earlier this month, but they don't seem to have given up on that indication. They're partnered with Astrazeneca.

Ashley
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News